Sunday, February 01, 2015 1:09:57 AM
Ebolacide has not even been tested in cell culture yet, much less small animals, much much less large animals, vastly less NHPs and in humans ( clinical trials) is not even on the distant horizon!
There are FOUR Ebola vaccines in Phase I's (two of which will start Phase II's this month, THREE more that have completed studies in NHPs and a few more in the earlier pre clinicals. ALL of which are ahead of NNVC and Four of which are at least five steps ahead of NNVC.
http://www.biopharma-reporter.com/Bio-Developments/Ebola-which-are-the-leading-vaccine-candidates
So if you say "there are no vaccines" just where does that leave Ebolacide?
Given where the vaccine candidates are and were Ebolacide is (totally out of sight behind back over the horizon) pointing out that "there is no Ebola vaccine" is less than meaningless.
PS Some of the vaccine candidates have had 100% protection in NHPs.+
PPS vaccines, in stark contrast to drugs, do not require field testing in humans. They can use challenge for efficacy and immunogenicity tests in primates to determine the relationship between immunogenicity and then do immunogenicity in humans and calculate the efficacy in humans. That's good enough for an approval and the resulting Priority Review Voucher.
If there are not enough case to field test (and there almost certainly will not be) by the time Ebolacide is ready (assuming it ever gets that far) Ebolacide will just have to sit on the shelf until the next outbreak, which could be many years. And by another outbreak there will almost inevitably be a stockpile of an effective vaccine on hand to deal with it.
Also note that NVAX has demonstrated in RSV trials (multiple successful Phase II's) the ability to very effective address the hidden protein in RSV which happens to be very similar to a a critical hidden protein in Ebola.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM